ERBB2 and breast cancer: Compared to trastuzamab, pertuzumab targets HER-2 receptor protein epitopes differently and has shown considerable improvement in survival rates.Combined with trastuzumab chemotherapy, pertuzumab has shown to significantly improve survival outcomes for HER2-positive breast cancer,has demonstrated potential therapeutic benefit in colorectal cancers with HER-2 amplification, but failed in HER-2 positive gastric cancers [12, 13].